| Literature DB >> 31191434 |
Samuel Stuart1, Valeria Belluscio1,2, Joseph F Quinn1, Martina Mancini1.
Abstract
Introduction: Mobility declines with age and further with neurodegenerative disorders, such as Parkinson's disease (PD). Walking and turning ability, in particular, are vital aspects of mobility that deteriorate with age and are further impaired in PD. Such deficits have been linked with reduction in automatic control of movement and the need for compensatory cognitive cortical control via the pre-frontal cortex (PFC), however the underlying neural mechanisms remain unclear. Establishing and using a robust methodology to examine PFC activity during continuous walking and turning via mobile functional near infra-red spectroscopy (fNIRS) may aid in the understanding of mobility deficits and help with development of appropriate therapeutics. This study aimed to: (1) examine test re-test reliability of PFC activity during continuous turning and walking via fNIRS measurement; and (2) compare PFC activity during continuous turning and walking in young, old and Parkinson's subjects.Entities:
Keywords: Parkinson's disease; fNIRS; pre-frontal cortex; turning; walking
Year: 2019 PMID: 31191434 PMCID: PMC6540937 DOI: 10.3389/fneur.2019.00536
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Participant demographic characteristics.
| Age (years) | 32.3 ± 7.5 | 65.38 (6.95) | 69.29 (4.05) | |
| Gender | F (15)/M (10) | F (10)/M (9) | F (8)/M (16) | 0.160 |
| Height (cm) | 1.70 (0.11) | 1.67 (0.10) | 1.62 (0.13) | |
| Weight (kg) | 70.86 (13.95) | 73.51 (15.42) | 77.47 (14.56) | 0.287 |
| MoCA | 28.67 (1.24) | 27.47 (3.91) | 27.69 (3.29) | 0.227 |
| Disease duration (years) | – | – | 9.88 (6.37) | – |
| MDS-UPDRS III | – | – | 36.54 (11.90) | – |
| FOGQ | – | – | 6.54 (8.18) | – |
| LEDD | – | – | 861.34 (499.07) | – |
| H&Y | – | – | I (0)/II (21)/III (3) | – |
UPDRS III, unified Parkinson's disease rating scale—motor subsection, FOGQ, freezing of gait questionnaire, LEDD, levodopa equivalent daily dosage, H&Y, Hoehn and Yahr scale.
Significance p < 0.05 should be in bold.
Reliability of fNIRS recording of PFC activity in young adults.
| Turning ( | Overall | B/L | −0.02 (0.25) | −0.01 (0.33) | 0.02 | 0.859 | 0.673 (0.245 to 0.857) | 0.819 |
| L | −0.02 (0.19) | 0.03 (0.55) | 0.12 | 0.297 | 0.512 (−0.093 to 0.784) | 1.162 | ||
| R | 0.03 (0.28) | 0.01 (0.27) | −0.01 | 0.745 | 0.658 (0.213 to 0.850) | 0.823 | ||
| Early | B/L | −0.02 (0.19) | −0.02 (0.27) | 0.02 | 0.863 | 0.793 (0.517 to 0.911) | 0.616 | |
| Late | B/L | 0.01 (0.33) | 0.01 (0.43) | 0.00 | 0.959 | 0.709 (0.316 to 0.875) | 0.919 | |
| Walking ( | Overall | B/L | −0.19 (0.24) | −0.18 (0.41) | 0.04 | 0.940 | 0.714 (0.239 to 0.891) | 0.925 |
| L | −0.23 (0.33) | −0.19 (0.64) | 0.09 | 0.786 | 0.685 (0.164 to 0.880) | 1.355 | ||
| R | −0.15 (0.32) | 0.18 (0.36) | −0.03 | 0.682 | 0.709 (0.231 to 0.889) | 0.938 | ||
| Early | B/L | −0.16 (0.26) | −0.17 (0.34) | −0.04 | 0.897 | 0.520 (−0.511 to 0.846) | 0.831 | |
| Late | B/L | −0.17 (0.34) | −0.17 (0.51) | 0.07 | 0.977 | 0.707 (0.220 to 0.888) | 1.224 | |
| Average | Overall | B/L | – | – | 0.03 | – | 0.668 (0.154 to 0.867) | 0.961 |
Trial 2 minus Trial 1, PFC, pre-frontal cortex; ICC, Intra-class correlation coefficient; CI, confidence interval; LoA, limits of agreement; B/L, bilateral; L, left; R, right. * p < 0.05.
Figure 1Bland Altman plots demonstrating agreement between the two 2-min trials of walking for overall PFC activity, Left and Right PFC activity, and Early and Late PFC activity. Dashed lines represent LoA.
Figure 2Bland Altman plots demonstrating agreement between the two 2-min trials of turning for overall PFC activity, Left and Right PFC activity, and Early and Late PFC activity. Dashed lines represent LoA.
Relative change in HbO2 during turning and walking in young, old and Parkinson's participants.
| Turning | Overall | B/L | −0.01 (0.25) | 0.01 (0.30) | 0.06 (0.35) | 0.464 | 0.647 | 0.059 | – |
| L | −0.06 (0.34) | 0.03 (0.30) | 0.05 (0.28) | 0.198 | – | ||||
| R | 0.03 (0.28) | 0.08 (0.33) | 0.09 (0.41) | 0.573 | – | ||||
| Early | B/L | −0.17 (0.19) | 0.04 (0.31) | 0.10 (0.26) | 0.114 | – | |||
| Late | B/L | −0.01 (0.31) | 0.02 (0.41) | 0.05 (0.46) | 0.646 | – | |||
| Walking | Overall | B/L | −0.26 (0.28) | −0.25 (0.36) | −0.03 (0.37) | 0.185 | |||
| L | −0.29 (0.32) | −0.21 (0.33) | −0.03 (0.37) | ||||||
| R | −0.21 (0.36) | −0.18 (0.40) | 0.02 (0.49) | 0.065 | – | ||||
| Early | B/L | −0.18 (0.30) | −0.14 (0.32) | 0.07 (0.29) | |||||
| Late | B/L | −0.29 (0.37) | −0.25 (0.43) | −0.10 (0.44) | 0.136 | – |
Significance p < 0.05 should be in bold. PFC, pre-frontal cortex; YA, young adults; OA, older adults; PD, Parkinson's disease; B/L, bilateral; L, left; R, right.
Effect sizes (Cohens d) for differences in HbO2 during turning and walking between groups.
| Turning | Overall | B/L | 0.08 | 0.24 | 0.16 |
| L | 0.28 | 0.36 | 0.07 | ||
| R | 0.17 | 0.18 | 0.03 | ||
| Early | B/L | 0.22 | |||
| Late | B/L | 0.09 | 0.16 | 0.07 | |
| Walking | Overall | B/L | 0.03 | ||
| L | 0.25 | ||||
| R | 0.08 | 0.45 | |||
| Early | B/L | 0.13 | |||
| Late | B/L | 0.10 | 0.48 | 0.35 |
Bold indicates effect size > 0.50 (medium effect). PFC, pre-frontal cortex; YA, young adults; OA, older adults; PD, Parkinson's disease; B/L, bilateral; L, left; R, right.